<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633397</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15110016</org_study_id>
    <nct_id>NCT02633397</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregory J. Kato, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled,
      parallel groups study aimed to evaluate the safety, tolerability and the efficacy of
      riociguat compared with placebo in patients with sickle cell disease (SCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized study involves 12 weeks of treatment with riociguat pills or placebo pills,
      and a follow-up period of 30 days after treatment. The dose is adjusted every 2 weeks based
      on systolic blood pressure (SBP) and well-being assessed at that visit. Physical
      examinations, vital signs, blood tests and questionnaires will be performed at 2 week
      intervals during the double blinded study treatment. Echocardiogram, urine testing,
      six-minute walk distance and questionnaires will be assessed at the beginning and end of the
      treatment phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall incidence of treatment emergent severe adverse events (SAE)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of SAE due to sickle cell related painful crisis</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidences of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain intensity using numerical pain score</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional exercise capacity by assessing 6 minute walk distance test</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure as the main pharmacodynamic variable</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of plasma NT-proBNP</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Modified Borg Dyspnoea Scale</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory measures</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of sickle cell related clinical complications</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tricuspid regurgitant velocity using non-invasive echocardiography</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain intensity using the Brief Pain Inventory</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain intensity using electronic daily pain diary piloted at selected sites</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat</intervention_name>
    <description>Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks</description>
    <arm_group_label>Riociguat</arm_group_label>
    <other_name>Adempas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Sickling disorder (HbSS, HbSC, HbSbeta-thalassemia, HbSD, HbSO-Arab documented by
             hemoglobin electrophoresis or HPLC fractionation)

          -  At least one of the following findings: a. Systolic blood pressure ≥ 130 mm Hg on at
             least two occasions at least 1 day apart (one of these may be by history), b.
             Macroalbuminuria as manifested by urine albumin to creatinine ratio &gt; 300 mg/g, c.
             Tricuspid regurgitant velocity (TRV) &gt; 2.9 m/sec measured by echocardiography d.
             NT-proBNP level ≥ 160 pg/mL e. Urinalysis protein 1 + or higher.

          -  Females of reproductive potential (FRP) must have a negative, pre-treatment pregnancy
             test. Post-menopausal women (defined as no menses for at least 1 year or post-surgical
             from bilateral oophorectomy) are not required to undergo a pregnancy test.

          -  Females of reproductive potential must agree to use reliable contraception when
             sexually active. Adequate contraception is defined as any combination of at least 2
             effective methods of birth control, of which at least one is a physical barrier (e.g.
             condoms with hormonal contraception or implants or combined oral contraceptives,
             certain intrauterine devices). Adequate contraception is required beginning at the
             signing of the informed consent form until one month after the last dose of riociguat.

          -  Patients must be willing to provide a blood sample for DNA analysis.

        Exclusion Criteria:

          -  Pregnant or breast feeding women

          -  Patients with severe hepatic impairment defined as Child Pugh C

          -  End stage renal disease requiring dialysis

          -  Patients with eGFR &lt;30 mL/min/1.73m, where GFR is estimated based on CKD-epi equation

          -  Patients on phosphodiesterase type 5 inhibitors (PDE-5) (such as sildenafil,
             tadalafil, vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or
             theophylline) or nitrates

          -  Patients on strong cytochrome P450 (CYP) and P-glycoprotein 1(P-gp)/BCRP inhibitors
             such as systemic azole antimycotics (eg: ketoconazole, itraconazole), or HIV protease
             inhibitors (such as ritonavir)

          -  Patients on St. John's Wort

          -  If patients are taking antihypertensive drugs or hydroxyurea prior to enrollment, they
             are excluded until the dose level is stable for at least three months

          -  Systolic blood pressure &lt;95 mm Hg at Screening Visit 1 or 2 or Week 0 before
             randomization

          -  Current enrollment in an investigational new drug trial. Patients are eligible for
             enrollment 30 days after the last dose of an investigational drug has been received

          -  Evidence of illicit drug use as documented by a positive urine toxicology screen
             within three months prior to enrollment

          -  Patients who have recently (last six months) experienced serious bleeding from the
             lung or have undergone a bronchial arterial embolization procedure.

          -  Pulmonary hypertension associated with Idiopathic Interstitial Pneumonias

          -  Medical disorder, condition, or history that in the investigator's judgement would
             impair the patient's ability to participate or complete this study or render the
             patient to be inappropriate for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Kato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregory Kato, MD</last_name>
    <phone>412-648-3017</phone>
    <email>katogj@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyn Newkirk, MEd</last_name>
    <phone>412-692-2437</phone>
    <email>can59@pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Morris, MD</last_name>
      <phone>404-727-5500</phone>
      <email>claudia.r.morris@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>April Zmitrovich</last_name>
      <phone>404-785-7135</phone>
      <email>april.zmitrovich@choa.org</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor R Gordeuk, MD</last_name>
      <phone>312-996-5680</phone>
      <email>vgordeuk@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aprille Mae Simbulan</last_name>
      <phone>312-996-8767</phone>
      <email>asimbu2@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Victor R Gordeuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Lanzkron, MD, MHS</last_name>
      <phone>410-502-8642</phone>
      <phone_ext>3</phone_ext>
      <email>slanzkr@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cedron Williams</last_name>
      <phone>410-502-6593</phone>
      <email>Cwill116@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Albert Einstein University/ Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Minniti, M.D.</last_name>
      <phone>718-920-4137</phone>
      <email>cminniti@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Kelsey Branch</last_name>
      <email>kebranch@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Caterina Minniti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Comprehensive Sickle Cell Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Ataga, MD</last_name>
      <phone>919-843-7708</phone>
      <email>kenneth_ataga@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Wichlan</last_name>
      <phone>919-966-6876</phone>
      <email>david_wichlan@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Ataga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marilyn Telen, MD</last_name>
      <phone>919-684-5378</phone>
      <email>marilyn.telen@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Brasswell</last_name>
      <phone>919-681-8645</phone>
      <email>angela.braswell@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marilyn Telen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Payal Desai, MD</last_name>
      <phone>614-293-2887</phone>
      <email>Payal.Desai@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Heinlein</last_name>
      <phone>614-293-5176</phone>
      <email>Melanie.Heinlein@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Payal Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Division of Hematology and Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura DeCastro, MD</last_name>
      <phone>412-623-7062</phone>
      <email>decastrolm@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>412-623-1100</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura DeCastro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Kanter, MD</last_name>
      <phone>843-792-2957</phone>
      <email>kanter@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Alston</last_name>
      <phone>843-876-8652</phone>
      <email>alstonch@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Kanter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wally Smith, M.D.</last_name>
      <phone>804-828-6938</phone>
      <email>wrsmith@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Sop</last_name>
      <phone>804-828-0810</phone>
      <email>daniel.sop@vcuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Wally Smith, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Gregory J. Kato, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>SCD</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Riociguat</keyword>
  <keyword>Adempas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

